Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Chronic Hepatitis B
Interventions
DRUG

Placebo

Placebo contains no active substance.

DRUG

TQA3334 Tablet

Inhibit viral replication.

DRUG

Nucleoside (acid) analogs (NAs)

Inhibit viral replication.

Trial Locations (15)

110000

The Sixth People's Hospital of Shenyang, Shenyang

130021

The first hospital of Jilin University, Changchun

214001

The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University), Wuxi

325200

People's Hospital Of RuiAn City, Rui’an

400016

The First Affiliated Hospital of Chongqing Medical University, Chongqing

410008

The Second XIANGYA Hospital Of Central South University, Changsha

430023

WuHan Jinyintan Hospital, Wuhan

510000

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

518036

Peking University Shenzhen Hospital, Shenzhen

545000

Hospital workers in Liuzhou, Liuzhou

610044

West China Hospital of Sichuan University, Chengdu

650034

First People's Hospital of Yunnan Province, Kunming

665099

Pu'er People's Hospital, Pu'er

710000

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an

831400

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY